Valuation: Roche Holding AG

Market Cap 279B 341B 300B 256B 481B 33,033B 489B 3,333B 1,300B 16,112B 1,281B 1,253B 55,897B P/E 2026 *
21x
P/E 2027 * 17.3x
Enterprise Value 289B 354B 311B 266B 499B 34,275B 508B 3,458B 1,349B 16,718B 1,329B 1,300B 58,000B EV / Sales 2026 *
4.63x
EV / Sales 2027 * 4.33x
Free-Float
88.78%
Yield 2026 *
2.86%
Yield 2027 * 2.93%
1 day-1.35%
Current month+3.91%
6 months-1.33%
Current year+2.04%
Current year 315.6
Extreme 315.6
374.9
1 year 243.9
Extreme 243.9
374.9
3 years 212.9
Extreme 212.9
374.9
5 years 212.9
Extreme 212.9
404.2
10 years 206.35
Extreme 206.35
404.2
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 326B
+1.97%+1.43%+48.44%+156.66% 1,037B
+1.42%+3.72%+53.32%+52.34% 615B
+1.43%+0.99%+34.83%+78.74% 448B
+1.85%+3.57%+37.09%+39.87% 293B
-0.11%+0.48%+18.87%+17.81% 264B
+0.25%-4.62%-27.66%-42.25% 216B
+1.49%-0.02%+20.14%+58.21% 198B
+0.40%-3.99%+15.23%+62.28% 162B
+0.77%-0.52%-1.38%-33.13% 141B
Average +0.78%+0.17%+22.10%+43.39% 374.78B
Weighted average by Cap. +1.11%+1.10%+34.02%+75.32%

Financials

2026 *2027 *
Net sales 62.42B 76.39B 67.19B 57.41B 108B 7,398B 110B 746B 291B 3,609B 287B 281B 12,519B 65.35B 79.99B 70.35B 60.11B 113B 7,746B 115B 781B 305B 3,778B 300B 294B 13,108B
Net income 13.93B 17.04B 14.99B 12.81B 24.02B 1,651B 24.45B 167B 64.95B 805B 63.98B 62.6B 2,793B 16.42B 20.1B 17.68B 15.1B 28.32B 1,946B 28.83B 196B 76.59B 949B 75.45B 73.82B 3,294B
Net Debt 10.48B 12.83B 11.28B 9.64B 18.08B 1,242B 18.4B 125B 48.88B 606B 48.16B 47.11B 2,102B 4.3B 5.26B 4.62B 3.95B 7.41B 509B 7.54B 51.37B 20.04B 248B 19.74B 19.31B 862B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA